Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT01894256
Other study ID # D0816C00006
Secondary ID 2013-002225-30
Status Active, not recruiting
Phase Phase 1
First received July 4, 2013
Last updated November 16, 2015
Start date November 2013
Est. completion date April 2016

Study information

Verified date November 2015
Source AstraZeneca
Contact n/a
Is FDA regulated No
Health authority Belgium: Federal Agency for Medicinal Products and Health ProductsBelgium: Institutional Review BoardNetherlands: The Central Committee on Research Involving Human Subjects (CCMO)Netherlands: Medical Ethics Review Committee (METC)Denmark: Danish Dataprotection AgencyDenmark: Ethics CommitteeUnited Kingdom: Medicines and Healthcare Products Regulatory AgencyUnited Kingdom: Research Ethics CommitteeFrance: Institutional Ethical Committee
Study type Interventional

Clinical Trial Summary

This is a 2-part study in patients with advanced solid tumours. Part A will investigate the PK of olaparib in patients with mild or moderate renal impairment compared to patients with normal renal function; Part B will allow eligible study patients continued access to olaparib after the PK phase and will provide additional safety data.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 57
Est. completion date April 2016
Est. primary completion date March 2015
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 75 Years
Eligibility Inclusion criteria:-

For inclusion in the study as a patient with renal impairment, the following criterion must be met:

1. Patients must have stable renal impairment (moderate or mild), depending on creatinine clearance estimated using the Cockcroft-Gault equation (moderate 31 to 50 mL/min; mild 51 to 80 mL/min), for at least 2 months prior to the start of the study. For inclusion in the study as a patient with normal renal function, the following criterion must be met:

2. Calculated serum creatinine clearance greater than or equal to 81 mL/min (using Cockcroft-Gault equation). All patients must fulfil the following criteria:

3. Provision of written informed consent prior to any study specific procedures .

4. Patients must be greater than or equal to 18 and less than or equal to 75 years of age.

5. Histologically or, where appropriate, cytologically confirmed malignant solid tumour refractory or resistant to standard therapy or for which no suitable effective standard therapy exists.

6. BMI between 18-30 kg/m2.

7. Normal liver and bone marrow function measured within 28 days prior to administration of IP as defined below: Haemoglobin (Hb) greater than or equal to 10.0 g/dL, with no blood transfusions in the previous 28 days.

Absolute neutrophil count (ANC) greater than or equal to 1.5 x 109/L. White blood cells (WBC) greater than 3 x 109/L. Platelet count greater than or equal to 100 x 109/L. Total bilirubin less than or equal to 1.5 x institutional upper limit of normal (ULN) (except in the case of Gilbert's disease).

Aspartate aminotransferase or serum glutamic oxaloacetic transaminase (AST), alanine aminotransferase or serum glutamic pyruvic transaminase (ALT) less than or equal to 2.5 x institutional ULN unless liver metastases are present in which case it must be less than or equal to 5x ULN.

8. Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.

9. Patients must have a life expectancy greater than or equal to 12 weeks.

10. Evidence of non childbearing status for women of childbearing potential, or postmenopausal status: negative urine or serum pregnancy test within 28 days of study treatment, confirmed prior to treatment on Day 1 of the first treatment period in Part A. Postmenopausal is defined as:

Amenorrheic for 1 year or more following cessation of exogenous hormonal treatments.

Luteinising hormone and follicle-stimulating hormone levels in the postmenopausal range for women under 50 years of age.

Radiation-induced oophorectomy with last menses greater than 1 year ago. Chemotherapy-induced menopause with greater than 1 year interval since last menses Surgical sterilisation (bilateral oophorectomy or hysterectomy).

11. Patients are willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations.

12. Patients must be on a stable concomitant medication regimen (with the exception of electrolyte supplements), defined as no changes in medication or in dose within 2 weeks prior to start of olaparib dosing, except for bisphosphonates, denosumab and corticosteroids, which should be stable for at least 4 weeks prior to start of olaparib dosing.

Exclusion criteria:-

Patients must not enter the study if any of the following exclusion criteria are fulfilled:

1. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff, its agents and/or staff at the study site).

2. Previous enrolment in the present study.

3. Participation in another clinical study with an investigational medicinal product (IP) during the last 14 days (or a longer period depending on the defined characteristics of the agent used).

4. Renal transplant and end stage renal disease (ESRD) patients.

5. Patients receiving any systemic chemotherapy or radiotherapy (except for palliative reasons) within 2 weeks prior to study treatment (or a longer period depending on the defined characteristics of the agents used). The patient can receive a stable dose of bisphosphonates or denosumab for bone metastases before and during the study as long as these were started at least 4 weeks prior to treatment.

6. Patients who have received or are receiving inhibitors or inducers of CYP3A4 within the washout period.

7. For Part A only, drugs which affect creatinine clearance such as cephalosporin antibiotics, ascorbic acid, trimethoprim, cimetidine and quinine should not be used within the 7 days prior to dosing with olaparib.

8. Treatment in the previous 3 months with any drug known to have a well-defined potential for hepatotoxicity (eg, halothane).

9. Persistent toxicities (greater than or equal to CTCAE Grade 2) caused by previous cancer therapy, excluding alopecia.

10. Patients with myelodysplastic syndrome/acute myeloid leukaemia.

11. Patients with symptomatic uncontrolled brain metastases. A scan to confirm the absence of brain metastases is not required. Patients with asymptomatic brain metastases or with symptomatic but stable brain metastases can receive a stable dose of corticosteroids before and during the study as long as these were started at least 4 weeks prior to treatment.

12. Major surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of major surgery.

13. Patients considered a poor medical risk due to a serious uncontrolled medical disorder, non malignant systemic disease, uncontrolled seizures, or active uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, extensive bilateral interstitial lung disease on high resolution computer tomography (HRCT) scan, or any psychiatric disorder that prohibits obtaining informed consent.

14. Patients with a history of heart failure or left ventricular dysfunction.

15. Patients who have gastric, gastro-oesophageal or oesophageal cancer.

16. Patients unable to swallow orally administered medication and patients with gastrointestinal disorders or significant gastrointestinal resection likely to interfere with the absorption of olaparib.

17. Breastfeeding women.

18. Immunocompromised patients eg, patients who are known to be serologically positive for human immunodeficiency virus (HIV).

19. Patients with known active hepatic disease (eg, hepatitis B or C).

20. Patients with a known hypersensitivity to olaparib or any of the excipients of the product.

21. Resting ECG at screening with measurable QTc greater than 470 msec at 2 or more time points within a 24 hour period or family history of long QT syndrome.

22. Clinical judgment by the investigator that the patient should not participate in the study.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label


Related Conditions & MeSH terms


Intervention

Drug:
Olaparib tablet dosing
Part A - single 300mg oral dose olaparib (administered as 2x150mg tablets) Part B - 300mg oral dose olaparib (administered as 2x150mg tablets) bd

Locations

Country Name City State
Belgium Research Site Brussels (Jette)
Belgium Research Site Edegem
Belgium Research Site Leuven
Belgium Research Site Liege
Belgium Research Site Wilrijk
Denmark Research Site Herlev
Denmark Research Site København Ø
France Research Site Bordeaux
France Research Site Dijon
Netherlands Research Site Amsterdam
Netherlands Research Site Maastricht
United Kingdom Research Site Newcastle Upon Tyne
United Kingdom Research Site Surrey

Sponsors (1)

Lead Sponsor Collaborator
AstraZeneca

Countries where clinical trial is conducted

Belgium,  Denmark,  France,  Netherlands,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Changes in plasma protein binding of olaparib and subsequent effects on pharmacokinetics: free maximum plasma concentration of unbound olaparib (Cmax) In Part A, plasma protein binding at 1 hour after dosing, used to calculate free Cmax (Cmax of unbound olaparib) Blood sample taken at 1 hour post first olaparib dose No
Other Changes in plasma protein binding of olaparib and subsequent effects on pharmacokinetics: free area under the plasma concentration-time curve from zero to infinity of unbound olaparib (AUC) In Part A, plasma protein binding at 1 hour after dosing, used to calculate free AUC (AUC of unbound olaparib) Blood sample taken at 1 hour post first olaparib dose No
Other Changes in plasma protein binding of olaparib and subsequent effects on pharmacokinetics: free apparent plasma clearance of unbound olaparib (CL/F) In Part A, plasma protein binding at 1 hour after dosing, used to calculate unbound CL/F (CL/F of unbound olaparib) Blood sample taken at 1 hour post first olaparib dose No
Primary Pharmacokinetics of olaparib: maximum olaparib concentration (Cmax) In Part A, the following variable will be calculated for olaparib where the data allow: maximum plasma concentration (Cmax). Pharmacokinetics will not be measured in Part B Blood samples will be collected on Day 1 of Part A at these time points: pre-dose, 0.25,0.5,1,1.5,2,3,4,6,8,12,24,48,72 and 96 hours post-dose. No
Primary Pharmacokinetics of olaparib : time to maximum concentration (tmax) In Part A, the following variable will be calculated for olaparib where the data allow: time to reach maximum plasma concentration (tmax). Pharmacokinetics will not be measured in Part B Blood samples will be collected on Day 1 of Part A at these time points: pre-dose, 0.25,0.5,1,1.5,2,3,4,6,8,12,24,48,72 and 96 hours post-dose. No
Primary Pharmacokinetics of olaparib: area under the plasma concentration-time curve from zero to the last measurable time point (AUC0-t) In Part A, the following variable will be calculated for olaparib where the data allow: area under the plasma concentration-time curve from zero to the last measurable time point (AUC0-t). Pharmacokinetics will not be measured in Part B Blood samples will be collected on Day 1 of Part A at these time points: pre-dose, 0.25,0.5,1,1.5,2,3,4,6,8,12,24,48,72 and 96 hours post-dose. No
Primary Pharmacokinetics of olaparib : area under the plasma concentration-time curve from zero to infinity (AUC) In Part A, the following variable will be calculated for olaparib where the data allow: area under the plasma concentration-time curve from zero to infinity (AUC). Pharmacokinetics will not be measured in Part B Blood samples will be collected on Day 1 of Part A at these time points: pre-dose, 0.25,0.5,1,1.5,2,3,4,6,8,12,24,48,72 and 96 hours post-dose. No
Primary Pharmacokinetics of olaparib : apparent plasma clearance following oral administration (CL/F) In Part A, the following variable will be calculated for olaparib where the data allow: apparent plasma clearance following oral administration (CL/F). Pharmacokinetics will not be measured in Part B Blood samples will be collected on Day 1 of Part A at these time points: pre-dose, 0.25,0.5,1,1.5,2,3,4,6,8,12,24,48,72 and 96 hours post-dose. No
Primary Pharmacokinetics of olaparib : terminal half-life (t½) In Part A, the following variable will be calculated for olaparib where the data allow: terminal half-life (t½). Pharmacokinetics will not be measured in Part B Blood samples will be collected on Day 1 of Part A at these time points: pre-dose, 0.25,0.5,1,1.5,2,3,4,6,8,12,24,48,72 and 96 hours post-dose. No
Primary Pharmacokinetics of olaparib : apparent volume of distribution (Vz/F) In Part A, the following variable will be calculated for olaparib where the data allow: apparent volume of distribution (Vz/F). Pharmacokinetics will not be measured in Part B Blood samples will be collected on Day 1 of Part A at these time points: pre-dose, 0.25,0.5,1,1.5,2,3,4,6,8,12,24,48,72 and 96 hours post-dose. No
Primary Pharmacokinetics of olaparib : terminal rate constant (?z) In Part A, the following variable will be calculated for olaparib where the data allow: terminal rate constant (?z). Pharmacokinetics will not be measured in Part B Blood samples will be collected on Day 1 of Part A at these time points: pre-dose, 0.25,0.5,1,1.5,2,3,4,6,8,12,24,48,72 and 96 hours post-dose. No
Primary Pharmacokinetics of olaparib : renal clearance (CLR) In Part A, the following variable will be calculated for olaparib where the data allow: renal clearance (CLR). Pharmacokinetics will not be measured in Part B Blood samples will be collected on Day 1 of Part A at these time points: pre-dose, 0.25,0.5,1,1.5,2,3,4,6,8,12,24,48,72 and 96 hours post-dose. No
Secondary Assessment of the safety and tolerability of olaparib by collection of adverse event reports Assessment of adverse events (AEs) graded by Common Terminology Criteria for Adverse Events (CTCAE) v4.0 From baseline, every visit until 30 days after last dose, assessed up to 20 months. Yes
Secondary Determine safety and tolerability of olaparib by assessment of 12 lead Electrocardiograms Assessment of standard 12 lead electrocardiograms (ECGs) Part A: baseline, days 1 and 3. Part B: Day 1 then every 4 weeks. Final assessment within 30 days after last dose. Yes
Secondary Determine safety and tolerability of olaparib by physical examination Assessment of physical examination Part A: baseline, day -1 and within 30 days after last dose. Part B: Day 1. Yes
Secondary Determine safety and tolerability of olaparib by assessment of vital signs Assessment of standard vital signs (including blood pressure, pulse) Part A: baseline, days 1,2 and 3. Part B: Days 1,8,15,22,29 then every 4 weeks. Final assessment within 30 days after last dose. Yes
Secondary Determine safety and tolerability of olaparib by assessment of body temperature Assessment of standard vital signs (body temperature) Part A: baseline, day 1. Part B: Days 1,8,15,22,29 then every 4 weeks. Final assessment within 30 days after last dose. Yes
Secondary Determine safety and tolerability of olaparib by assessment of clinical chemistry results Assessment of laboratory parameters (clinical chemistry) Part A: baseline, days -1 and 3. Part B: Days 1,8,15,22,29 then every 4 weeks. Final assessment within 30 days after last dose. Yes
Secondary Determine safety and tolerability of olaparib by assessment of haematology results Assessment of laboratory parameters (haematology) Part A: baseline, days -1 and 3. Part B: Days 1,8,15,22,29 then every 4 weeks. Final assessment within 30 days after last dose. Yes
Secondary Determine safety and tolerability of olaparib by assessment of urinalysis results Assessment of laboratory parameters (urinalysis) Part A: baseline, days -1 and 3. Part B: Days 1,8,15,22,29 then every 4 weeks. Final assessment within 30 days after last dose. Yes
See also
  Status Clinical Trial Phase
Completed NCT03315091 - Phase I Study to Assess the Effect of Food on AZD1775 Pharmacokinetics in Patients With Advanced Solid Tumours Phase 1
Completed NCT01921140 - To Determine the Effect of Food on the Pharmacokinetics of Olaparib and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours Phase 1
Completed NCT00732420 - Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors Phase 1
Recruiting NCT03572192 - Tissue Collection Framework To Improve Outcomes In Solid Tumours
Completed NCT02360345 - Phase I Trial of ONX-0801 Once Weekly or Alternate Weekly Phase 1
Completed NCT02264418 - Safety and Tolerability of ODM-203 in Subjects With Advanced Solid Tumours Phase 1
Completed NCT02093351 - To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer Phase 1
Completed NCT01956669 - Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors Phase 2
Recruiting NCT02263950 - A Phase 1/2a Study of LON002 in Subjects With Advanced Solid Tumours Phase 1/Phase 2
Recruiting NCT02215850 - Safety Study of SLC-0111 in Subjects With Advanced Solid Tumours Phase 1
Completed NCT01931761 - Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C] Selumetinib in Volunteers Phase 1
Completed NCT01900028 - To Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of Olaparib, and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation to Patients With Advanced Solid Tumours Phase 1
Completed NCT00136578 - Ispinesib In Combination With Carboplatin In Patients With Solid Tumors Phase 1
Completed NCT01184274 - A Phase I Study of SB939 in Pediatric Patients With Refractory Solid Tumours and Leukemia Phase 1
Withdrawn NCT03266159 - A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity of GSK525762 Plus Trametinib in Subjects With Solid Tumors Phase 2
Completed NCT01974349 - To Assess the Effect of Food on the Pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers Phase 1
Completed NCT02923947 - Study to Assess Osimertinib in Patients w/ Adv Solid Tumours & Normal Kidney Function or Severe Kidney Impairment Phase 1
Completed NCT02063204 - To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Renal Impaired Subjects and Healthy Subjects Phase 1
Completed NCT02056392 - To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers Phase 1
Completed NCT00742131 - A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally to Subjects With Solid Tumors Phase 1